Psoriasis Clinical Trial
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
Summary
A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.
Eligibility Criteria
Inclusion Criteria:
At least 6 months history of moderate or severe PPP, as defined by PPPASI ≥12 and PPPGA ≥3 at screening
Males and females must be willing to use birth control as indicated
Exclusion Criteria:
Moderate to severe psoriasis covering ≥10% of total body surface area (BSA) at screening
Breastfeeding or pregnant
Known immunodeficiency or subject is immunocompromised
Active/latent infection with HBV, HCV, HIV, SARS-CoV-2 or TB
Any topical medications for PPP excluding emollients within two weeks of randomization and systemic therapies (including phototherapy) within 4 weeks of randomization
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 51 Locations for this study
Birmingham Alabama, 35205, United States
Bryant Arkansas, 72022, United States
San Diego California, 92121, United States
Santa Monica California, 90404, United States
Coral Gables Florida, 33134, United States
Hollywood Florida, 33021, United States
North Miami Beach Florida, 33162, United States
Sandy Springs Georgia, 30328, United States
Indianapolis Indiana, 46250, United States
Louisville Kentucky, 40241, United States
Bay City Michigan, 48706, United States
Saint Louis Missouri, 63108, United States
Omaha Nebraska, 68144, United States
Portsmouth New Hampshire, 03801, United States
Dublin Ohio, 43016, United States
Mayfield Heights Ohio, 44124, United States
Norman Oklahoma, 73071, United States
Pittsburgh Pennsylvania, 15212, United States
San Antonio Texas, 78229, United States
Edmonton Alberta, T6G 1, Canada
Edmonton Alberta, T6H 4, Canada
Red Deer Alberta, T4P 1, Canada
Barrie Ontario, L4M 7, Canada
Markham Ontario, L3P 1, Canada
Québec , G1V 4, Canada
Kutná Hora , 284 0, Czechia
Prague , 100 0, Czechia
Prague , 150 0, Czechia
Augsburg , 86156, Germany
Bad Bentheim , 48455, Germany
Dresden , 01307, Germany
Erlangen , 91054, Germany
Hamburg , 20537, Germany
Kiel , 24105, Germany
Mahlow , 15831, Germany
München , 80337, Germany
Münster , 48149, Germany
Osnabrück , 49074, Germany
Stuttgart , 70178, Germany
Budapest , 1085, Hungary
Debrecen , 4012, Hungary
Kecskemét , 6000, Hungary
Pécs , 7632, Hungary
Kraków , 31-55, Poland
Lublin , 20-07, Poland
Lublin , 20-57, Poland
Warsaw , 01-14, Poland
Warsaw , 02-96, Poland
Wrocław , 50-56, Poland
Wrocław , 51-31, Poland
Salford , M6 8H, United Kingdom
How clear is this clinincal trial information?